Paper36978351
Current and Emerging Inhaled Antibiotics for Chronic Pulmonary Pseudomonas aeruginosa and Staphylococcus aureus Infections in Cystic Fibrosis.
Li D and 1 other. Antibiotics (Basel), 2023. Cited by 34 papers, by iCite.
Cite this record
ConductScience Library. Current and Emerging Inhaled Antibiotics for Chronic Pulmonary Pseudomonas aeruginosa and Staphylococcus aureus Infections in Cystic Fibrosis. Papers, record 36978351. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36978351
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Current and Emerging Inhaled Antibiotics for Chronic Pulmonary Pseudomonas aeruginosa and Staphylococcus aureus Infections in Cystic Fibrosis.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References94
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19805554 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. | Antimicrob Agents Chemother | 2010 | https://conductscience.org/library/papers/19805554 | PubMed |
| 2 | 25753888 | The use of vancomycin with its therapeutic and adverse effects: a review. | Eur Rev Med Pharmacol Sci | 2015 | https://conductscience.org/library/papers/25753888 | PubMed |
| 3 | 30073802 | Biology and management of methicillin resistant Staphylococcus aureus in cystic fibrosis. | Pediatr Pulmonol | 2018 | https://conductscience.org/library/papers/30073802 | PubMed |
| 4 | 8146414 | Nebulized colistin causes chest tightness in adults with cystic fibrosis. | Respir Med | 1994 | https://conductscience.org/library/papers/8146414 | PubMed |
| 5 | 25278817 | Colistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapy. | Core Evid | 2014 | https://conductscience.org/library/papers/25278817 | PubMed |
| 6 | 21075062 | Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. | J Cyst Fibros | 2011 | https://conductscience.org/library/papers/21075062 | PubMed |
| 7 | 34384254 | Management of chronic Pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis. | Future Microbiol | 2021 | https://conductscience.org/library/papers/34384254 | PubMed |
| 8 | 16687478 | Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. | Proc Natl Acad Sci U S A | 2006 | https://conductscience.org/library/papers/16687478 | PubMed |
| 9 | 18658109 | Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. | Am J Respir Crit Care Med | 2008 | https://conductscience.org/library/papers/18658109 | PubMed |
| 10 | 32807645 | Long-term safety study of colistimethate sodium (Colobreathe®): Findings from the UK Cystic Fibrosis Registry. | J Cyst Fibros | 2021 | https://conductscience.org/library/papers/32807645 | PubMed |
| 11 | 26573178 | Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin. | Future Microbiol | 2015 | https://conductscience.org/library/papers/26573178 | PubMed |
| 12 | 34144923 | Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection. | J Cyst Fibros | 2021 | https://conductscience.org/library/papers/34144923 | PubMed |
| 13 | 20735333 | Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment. | Scand J Infect Dis | 2010 | https://conductscience.org/library/papers/20735333 | PubMed |
| 14 | 10926333 | A ten year review of colomycin. | Respir Med | 2000 | https://conductscience.org/library/papers/10926333 | PubMed |
| 15 | 15705991 | Bronchial constriction and inhaled colistin in cystic fibrosis. | Chest | 2005 | https://conductscience.org/library/papers/15705991 | PubMed |
| 16 | 31447669 | Antimicrobial Treatment of Staphylococcus aureus in Patients With Cystic Fibrosis. | Front Pharmacol | 2019 | https://conductscience.org/library/papers/31447669 | PubMed |
| 17 | 22354300 | In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection. | Antimicrob Agents Chemother | 2012 | https://conductscience.org/library/papers/22354300 | PubMed |
| 18 | 3301785 | Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. | J Antimicrob Chemother | 1987 | https://conductscience.org/library/papers/3301785 | PubMed |
| 19 | 32566909 | Metabolomic Description of Ivacaftor Elevating Polymyxin B Mediated Antibacterial Activity in Cystic Fibrosis Pseudomonas aeruginosa. | ACS Pharmacol Transl Sci | 2020 | https://conductscience.org/library/papers/32566909 | PubMed |
| 20 | 2170321 | Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed beta-lactamase producing strains. | J Antimicrob Chemother | 1990 | https://conductscience.org/library/papers/2170321 | PubMed |
Cited by20
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 34 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42747544 | Inhalable Dry Powders of Antimicrobial Agents in Respiratory Diseases. | Lung | 2026 | https://conductscience.org/library/papers/42747544 | PubMed |
| 42041359 | Detection to Disruption: A Comprehensive Review of Bacterial Biofilms and Therapeutic Advances. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/42041359 | PubMed |
| 41898631 | Distinct CFTR Mutation Spectrum and Atypical Clinical Presentations in Chinese Patients with Cystic Fibrosis. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41898631 | PubMed |
| 41583061 | Liposomal antimicrobials in the fight against bacterial and fungal pathogens: Clinical successes and development challenges. | Int J Pharm X | 2026 | https://conductscience.org/library/papers/41583061 | PubMed |
| 41416830 | Inhaled liposomal ciprofloxacin protects against lethal tularemia in the common marmoset. | Antimicrob Agents Chemother | 2026 | https://conductscience.org/library/papers/41416830 | PubMed |
| 41364184 | Sub-inhibitory tobramycin concentration suppresses ToxA and LipA in single- and dual-species biofilms. | Braz J Microbiol | 2025 | https://conductscience.org/library/papers/41364184 | PubMed |
| 41328407 | Phenotypic and Molecular Analysis of Fosfomycin Resistance Among P. aeruginosa Isolates from Cystic Fibrosis Patients. | Infect Drug Resist | 2025 | https://conductscience.org/library/papers/41328407 | PubMed |
| 41083887 | Bacterial cell envelope-targeting antibiotics. | Nat Rev Microbiol | 2026 | https://conductscience.org/library/papers/41083887 | PubMed |
| 40871096 | Latest Advances in Inhalable Dry Powder Bacteriophage Therapy for Pulmonary Infections. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/40871096 | PubMed |
| 40284567 | Diversification of Pseudomonas aeruginosa After Inhaled Tobramycin Therapy of Cystic Fibrosis Patients: Genotypic and Phenotypic Characteristics of Paired Pre- and Post-Treatment Isolates. | Microorganisms | 2025 | https://conductscience.org/library/papers/40284567 | PubMed |
| 40223951 | Comparative efficacy and safety of inhaled antibiotics in managing chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis and bronchiectasis: a systematic review and network meta-analysis. | J Thorac Dis | 2025 | https://conductscience.org/library/papers/40223951 | PubMed |
| 40001425 | Eisenia bicyclis-Mediated Gold Nanoparticles Exhibit Antibiofilm and Antivirulence Activities Against Pseudomonas aeruginosa and Staphylococcus aureus. | Antibiotics (Basel) | 2025 | https://conductscience.org/library/papers/40001425 | PubMed |
| 39779734 | DJK-5, an anti-biofilm peptide, increases Staphylococcus aureus sensitivity to colistin killing in co-biofilms with Pseudomonas aeruginosa. | NPJ Biofilms Microbiomes | 2025 | https://conductscience.org/library/papers/39779734 | PubMed |
| 39771486 | Development and Characterization of Spray-Dried Combined Levofloxacin-Ambroxol Dry Powder Inhaler Formulation. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/39771486 | PubMed |
| 39334985 | Murepavadin Enhances the Killing Efficacy of Ciprofloxacin against Pseudomonas aeruginosa by Inhibiting Drug Efflux. | Antibiotics (Basel) | 2024 | https://conductscience.org/library/papers/39334985 | PubMed |
| 38816673 | Structural Insights into the Lipopolysaccharide Transport (Lpt) System as a Novel Antibiotic Target. | J Microbiol | 2024 | https://conductscience.org/library/papers/38816673 | PubMed |
| 38702073 | Considerations for the use of inhaled antibiotics for Pseudomonas aeruginosa in people with cystic fibrosis receiving CFTR modulator therapy. | BMJ Open Respir Res | 2024 | https://conductscience.org/library/papers/38702073 | PubMed |
| 38172634 | A novel antibiotic class targeting the lipopolysaccharide transporter. | Nature | 2024 | https://conductscience.org/library/papers/38172634 | PubMed |
| 38019899 | Structure-Interaction Relationship of Polymyxins with Lung Surfactant. | J Med Chem | 2023 | https://conductscience.org/library/papers/38019899 | PubMed |
| 37764311 | Development of Quinazolinone Derivatives as Modulators of Virulence Factors of Pseudomonas aeruginosa Cystic Fibrosis Strains. | Molecules | 2023 | https://conductscience.org/library/papers/37764311 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CFTR | 1080 | PubTator's text mining | https://conductscience.org/library/genes/1080 | NCBI Gene |
| TOP2A | 7153 | PubTator's text mining | https://conductscience.org/library/genes/7153 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36978351
GET https://conductscience.org/api/papers/v1/36978351/references?page=2